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data to calculate direct, indirect and intangible costs in patients receiving ART.
METHODS: Multicenter prospective observational study in eight German special-
ized centres for infectious diseases: four private practices/outpatient centres and
four hospitals offering inpatient- and outpatient facilities. CORSAR started recruit-
ment during 2009 and ends in July 2012, when the last patient reaches week 96.
After signing informed consent, patients were included and stratified by treatment
line. Treatment history and concomitant therapy were taken from the patients’
records. Direct costs for hospitalization, outpatient care, other medical care and
treatment as well as out of pocket payments and quality of life data were calculated
from the data collected by quarterly questionnaires. RESULTS: A total of 1154 pa-
tients with a mean age 47.5y receiving ART were included. Time since HIV-diagno-
sis was10.6 years, 10.2% had viral load50 cp/ml; 10.6% female; employment ratio
60.8%. Direct costs of treatment were mainly driven by antiretroviral drugs, ac-
counting for 83.3%. Due to use of less complex ART-regimens and more frequent
use of NNRTI-based ART in earlier treatment lines total costs were highest in ad-
vanced treatment-lines (3rd) with 26,243 €/year compared to 22,718 €/year for
initial therapy. The labour market participation rate also decreases with advance-
ment in treatment lines (65% in first treatment line vs. 46% in3rdtreatment lines).
Indirect cost due to productivity losses account for 7% of total costs.
CONCLUSIONS: Total costs were higher in later lines of therapy due to more com-
plex, less NNRTI-based regimens. In comparison to earlier studies the impact of
Non-ART-costs decreased. Expenses to be borne by the patient increased but are
still less than 1%, indicating an increasing financial burden of people living with
HIV by their disease within the German health system.
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OBJECTIVES: Prior trials have demonstrated efficacy and effectiveness of po-
saconazole in the prophylaxis of invasive fungal diseases (IFDs) in high-risk pa-
tients. Controversy exists about the cost effectiveness of posaconazole prophylaxis
in neutropenic patients with a high risk of IFDs. We performed an analysis com-
paring the direct costs of posaconazole prophylaxis against topical polyene
(thrush) prophylaxis in patients with acute myelogenous leukemia (AML) and my-
elodysplastic syndrome (MDS). METHODS: Data of AML/MDS patients receiving
remission-induction chemotherapy were analysed to compare hospital costs of
patients before (2003-05) and after (2006-08) introduction of posaconazole prophy-
laxis. All cases were part of an earlier analysis demonstrating effectiveness of
posaconazole over topical prophylaxis. Duration on general ward, intensive care
unit, mechanical ventilation, diagnostic procedures and all anti-infective drugs
were included into the cost analysis. RESULTS: Patient groups were well matched
according to age, gender, underlying disease, and duration of neutropenia. The
average costs per patient in the posaconazole group (n76) and the topical polyene
group (n81) were 21,040 € (95% CI: 18,204-23,876 €) and 23,169 € (95% CI: 19,402-
26,937 €) per patient, respectively. Antifungal treatment costs were nominally
higher in the posaconazole group (4,580 € [95% CI: 3,678-5,482 €] vs. 4,019 € [95% CI:
2,825-5,214 €]). Costs for antibacterials (1,316 € [95% CI: 1,039-1,593 €] vs. 1,533 € [95%
CI: 1,238-1,827 €]) were numerically decreased in the posaconazole group. Average
duration of ICU stays were 1.79 (95% CI: 0.68-2.90) days per patient compared to 3.83
(95% CI: 1.53-6.13) days per patient. Costs for diagnostic procedures were 611 € (95%
CI: 478-744 €) and 653 € (95% CI: 552-754 €) per patient, respectively. CONCLUSIONS:
In our hospital, there was a trend towards cost-saving by posaconazole prophylaxis
in patients receiving remission-induction chemotherapy. These cost savings were
primarily caused by a shorter overall length of stay and the less frequent ICU
treatment of patients receiving posaconazole.
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COST OF ANTIMICROBIAL PRESCRIBING USING A LARGE PHARMACY
DATABASE IN SOUTH AFRICA
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OBJECTIVES: To provide a general overview of antimicrobial prescribing cost in a
South African primary care patient population whose prescriptions were dis-
pensed by community pharmacies. METHODS: A retrospective, cross-sectional
pharmacoepidemiological study was conducted on prescription data of a national
community pharmacy group in South Africa for 2010. All records for antimicrobials
were analysed. The MIMS classification system was used. RESULTS: A total of 660
500 patients received 1 576 593 antimicrobial products during 2010 (average of 2.39
products per year) at a total cost of R191 875 007. The average age of patients was
34.23 years. Most patients were females (58.32%), and they were prescribed 60.12%
of antimicrobial products. The average cost per antimicrobial product was R121.70
(SDR158.21). Antiviral agents were the most expensive (R195.67), followed by ami-
noglycosides (R188.42). The least expensive products were chloramphenicols
(R17.25) and sulphonamides and combinations (R22.68). Beta-lactams were the
most often prescribed class accounting for 36.02% of all antimicrobial prescrip-
tions. The average cost for a beta-lactam prescription was R99.53. The average cost
per over-the-counter product was R32.75, compared to R158.21 for prescription-
only antimicrobials. Most products were tablets (61.80%), followed by capsules
(16.25%) and suspensions (14.39%). Per prescription, the injections were the most
expensive (average of R343.85 per prescription), followed by ampoules (R324.56)
and solutions (R267.33). Creams were on average the least expensive (R31.24).
There was a clear peak in prescribing during the winter months (May to August).
The single most often prescribed trade name product was a generic combination
product of amoxicillin and clavulanic acid. On average, the most expensive trade
name product was Valcyte 450R tablets (valganciclovir) at R12 217.76.
CONCLUSIONS: This study provided a general overview of antimicrobial prescrib-
ing cost in a South African primary care patient population. Costs varied hugely
with generic prescribing influencing costs.
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OBJECTIVES: To analyze the changes in the highly active antiretroviral pharmaco-
therapy during the period 2006-2011 and its impact on cost and disease control of
HIV/AIDS patients in Bulgaria. METHODS: It is a combined retrospective and pro-
spective observational real life study on cost and therapeutic results of AIDS pa-
tient’s therapy. Information was gathered for 2/3 of the treated patients for the
antiretroviral combinations therapy and its cost, CD4 count and viral load. The
changes in the dosage regimes, cost of therapy and its influence on CD4 count and
viral load were evaluated. Descriptive statistic, Willcoxon tests, and Spearman
correlation analysis were applied. RESULTS: On total 162 patients were included
and out of them 48 identified with the changes in their therapy. Nearly 40 different
dosage regimes were found prescribed as combinations of 3 or 4 medicines. During
the period were introduces 3 new antiretroviral medicines (tenofovir, emtricit-
abine, darunavir). The average yearly cost of pharmacotherapy is increasing from
155 837.64 euro to 319 571.76 euro during 2006 - 2011. To all treatment naive pa-
tients were prescribed the newly authorized medicines that lead to sustained sup-
pression of viral load to20 in 45.46%. Introduction of the new medicines led to the
increase in total pharmacotherapy cost with 291 89.64 euro, but also to better
disease control. Statistically significant were the changes in the mean cost of ther-
apy in 2007 vs 2006 (p0,0002) and in 2010 vs 2009 (p 0,0001). We found the
statistically significant changes among the mean cost of therapy and viral load
(p0,0221), as well as among the mean cost of therapy and CD4 count (p0,05). The
correlation among the therapeutic results and the therapeutic combinations were
found in 2011 (p0,0064).CONCLUSIONS:AIDS remain costly disease for the health
insurance budget but new medicines led to better control on its progression.
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OBJECTIVES: To estimate the impact of initial empiric antibiotic treatment failure
on pharmacological and total health care costs in hospitalized patients with cIAIs.
METHODS: The economic impact associated with initial empiric antibiotic treat-
ment failure was based on the results of an observational epidemiological study
involving 201 adults with cIAI in Greece (NCT00929643). An average per patient-per
day DRG value was estimated based on diagnosis at discharge and DRG mapping.
Daily cost was then extrapolated to the additional length of stay (LOS), associated
with initial antibiotic failure. Costs included expenditure for additional ICU and
surgical interventions. DRG matching was validated by a specialist medical advi-
sor. Mean per patient DRGs were weighed against subject percentage in each diag-
nosis group. Mean per patient costs for unsuccessful initial therapies were calcu-
lated using the latest formulary prices and the mean number of days on each
antibiotic agent, as recorded in the observational study. RESULTS: The most fre-
quently reported diagnoses (201 subjects) were perforation of the intestine (15.9%),
acute appendicitis with peritoneal abscess (13.4%) and post–operative peritonitis
(13.4%). Patients most commonly received metronidazole (59.2%), followed by
b–lactamase inhibitors (38.3%) and second generation cephalosporines (30.3%) as
empiric antibiotic treatment (as part of monotherapy, double therapy or triple
therapy schemes). 78 patients exhibited failure of the initial treatment, whereas
initial treatment was successful in 111 subjects with respective hospitalization of
21.916.4 and 8.9  4.5 days. Total additional per patient resource cost was esti-
mated to be €3,761.56 inclusive of unsuccessful mean empiric antibiotic expendi-
ture, which was estimated to be €220.06 per patient. CONCLUSIONS: Retrospective
data collected for a 2-year period showed that a significant percentage (42.9%) of
patients exhibited failure of their initial antibiotic treatment. These patients had a
greater chance of requiring prolongation of hospitalization and more extensive use
of health care expenditure during times where resources are scarce.
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OBJECTIVES: The ESTIMATOR study aims to provide information on clinical and
economic outcomes associated with the management of fungal infections across
intensive care units (ICUs) in Greece. METHODS: ESTIMATOR was a non-interven-
tional prospective cohort study conducted in 14 ICUs in Greece. Adult patients
initiating therapy with a systemic antifungal agent between July 2011 and February
2012 were included. Information on predisposing factors, management and thera-
peutic strategies, clinical outcomes and length of ICU stay (LOICUS) were recorded
until end of therapy or death. RESULTS: A total of 155 eligible patients were re-
cruited. 68% of patients presented at least 5 predisposing factors for fungal infec-
tion at antifungal treatment (AT) onset, while the mean APACHE score was 22.4
(s.d. 5.9). Median time until AT initiation was 6 days after ICU admission, while the
median LOICUS was 31 days. 49.7% of patients received treatment with an empiric
strategy while prophylaxis, pre-emptive and definitive strategies where used at
6.4%, 20.0% and 23.9% of the study population respectively. Echinocandins (57.3%),
Fluconazole (20.0%) and Itraconazole (12.9%) were the most utilized therapies in
the study. The overall treatment success and mortality rates were 43.9% and 49.7%
respectively. Variations in death and response rates were observed when adjusted
to the treatment strategy and the class of drug used. The mean total cost per
patient treated was estimated at 22,012 Euros. Average LOICUS accounts for the
80.8% of total direct costs, while antifungal treatment, tests and investigations
account for the remaining 19.2%. Limited efficacy of first line antifungal agent is
associated with an increase in economic costs of 74%. CONCLUSIONS: Treating
patients for fungal infections imposes a high economic burden to hospitals. Signif-
icant cost drivers are prolonged LOICUS and treatment failure. Treatment options
that result in LOICUS reduction and increased first line efficacy have the potential
to reduce hospital cost.
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OBJECTIVES: Neisseria meningitidis is a leading cause of life-threatening invasive
meningococcal diseases (IMD). In most populated Canadian provinces, vaccination
with the monovalent vaccine (MenC; against serogroup C) is recommended at one
year of age. This study aimed to assess various quadrivalent vaccination strategies
(MenACWY-TT covering serogroups A, C, W135 and Y) schedule (12 months with
and without booster at 12 or 15 years) in Canada compared to the current strategy.
METHODS: IMD incidence under the different scenarios was estimated using a
dynamic model. The cost associated with IMD treatment, IMD sequelae and IMD
mortality were estimated. Input data (mortality, rates of sequelae and costs) were
retrieved from Canadian statistics and published studies. The time horizon was 50
years. A discount rate of 5% was applied on costs. Costs were estimated from the
third-party payer (TPP) and the societal perspective (accounting for the productivity lost
from IMD and its sequelae). Deterministic and probabilistic sensitivity analyses were
conducted. RESULTS: Compared with MenC at 12 months, MenACWY-TT at 12
months was estimated to prevent an additional 862 IMD cases and 76 deaths, 3,362
IMD cases and 296 deaths with a booster at 12 years and 4,007 IMD cases and 353
deaths with a booster at 15 years. The treatment costs averted while switching to
the MenACWY-TT vaccine were estimated at C$8.4 (no booster), C$31.9 ( booster
at 12 years) and C$39.6 millions ( booster at 15 years) from the TPP perspective and
respectively C$24.0, C$89.8 and C$112.2 millions from the societal perspective.
Results were most sensitive to the incidence of IMD and serogroup-specific inci-
dence of post-IMD sequelae. CONCLUSIONS: The model predicted that vaccinating
with MenACWY-TT at 12 months with an adolescent booster would result in addi-
tional IMD and cost reduction compared to the current MenC at 12 months.
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OBJECTIVES: SPRINT-2 and RESPOND-2 randomized clinical trials have demon-
strated substantially higher sustained virologic response rates (SVR) for bocepre-
vir-based treatment compared to peginterferon and ribavirin (PR) alone in patients
with chronic genotype 1 HCV infection. Our objective was to evaluate the cost-
effectiveness of using boceprevir in Germany from the perspective of German Stat-
utory Health Insurance (SHI). METHODS: A Markov model was created to project
the effect of antiviral therapy options on Hepatitis C disease progression using
German life tables and baseline patient demographics from the trials - mean age,
gender, and fibrosis stage distribution. The first part of the model simulated two
strategies - treatment with boceprevir/peginterferon/ribavirin (as defined by the
European Medicines Agency) and treatment with peginterferon/ribavirin. The sec-
ond part of the model projected lifetime incidences of decompensated cirrhosis,
hepatocellular carcinoma, liver-transplant, and liver-related death. All hepatitis
C-related state transition probabilities were obtained from previously published
studies. Pharmacy retail prices minus rebates (Social code book V, § 130 (1) and §
130a (1a)) were used. The model was validated with previously published studies
and probabilistic sensitivity analysis was performed. RESULTS: Liver-related mor-
bidity and mortality were projected to be reduced by 43% to 53%. for a quality
adjusted life year (QALY) gain of 0.8 in treatment naïve patients, and 1.4 in treat-
ment experienced patients in comparison with SOC. The cost per QALY gained on
boceprevir-based regimes compared to PR alone was 17,511€ for treatment naïve
patients and 16,645€ for treatment experienced patients in comparison with SOC.
CONCLUSIONS: In German SHI, the addition of boceprevir to PR in patients with
chronic genotype 1 HCV infection reduces liver-related morbidity and mortality in
a quantifiable and cost-effective fashion, irrespective of whether patients have
been previously treated.
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AND WALES: A DYNAMIC MODEL BASED ANALYSIS
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OBJECTIVES: Epidemiology of pertussis shows that despite effective vaccination in
childhood, naturally acquired and vaccine induced immunity is waning over time
leading to higher incidence in adolescents and adults. Literature estimates the
annual incidence of pertussis in the UK reaches 330/100,000 compared with an
incidence of 4/100,000 based on statutory notifications, highlighting the degree of
under-reporting. This analysis examines the cost-effectiveness of the addition of
an adolescent routine booster vaccination against pertussis to the schedule in
England and Wales from a payer perspective. METHODS: An age stratified, com-
partmental dynamic model was developed and calibrated on HPA data corrected
for symptomatic and asymptomatic cases and empirical contact rates. Two sce-
narios were compared: current pertussis vaccination schedule (2, 3, and 4 months
of age) and a similar schedule with additional booster vaccination at 15 years with
coverage of 59%. Total costs and quality adjusted life years (QALYs) were
estimated. RESULTS: At equilibrium pertussis booster vaccination at 15 years is
projected to reduce the combined reported and unreported incidence of pertussis
in the following age categories: 10-19 years (55.0%), 20-59 years (31.3%) and 60-75
years (27.9%). There are 7155 QALYs gained annually in the UK population. Unre-
ported symptomatic cases were assumed to incur no cost and 50% of the QALY
benefit of reported cases but provided 98% of the total quality of life gained through
total symptomatic cases. Annual implementation costs (£9.4M) would be partially
offset by savings associated with reported cases (£1.5M). The incremental cost per
QALY would be £1,103 from a payer perspective. CONCLUSIONS: Model projection
indicates that adolescent routine booster vaccination against pertussis would re-
duce pertussis burden, and is likely to be cost-effective from a payer perspective.
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COST-EFFECTIVENESS-ANALYSIS OF THE COMBINATION- THERAPY
TELAPREVIR, PEG-IFN2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC
HEPATITIS-C IN AUSTRIA
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OBJECTIVES: Due to the fact that an infection with the Hepatitis-C-Virus usually
runs chronic, this disease represents a major public-health challenge. Hence, the
aim of this study is to evaluate the treatment of the Hepatitis-C-Infection with the
standard-therapy Peg-IFN2a in combination with Ribavirin vs. the combination-
therapy Peg-IFN2a, Ribavirin and Telaprevir. METHODS: For the decision tree
analysis model, an extended cost-per-cure-analysis was performed. The used data
derived from two large-scale double-blind, randomized, placebo-controlled Phase-
III-Studies by Jacobson et al. (2011) and Zeuzem et al. (2011). The modeling was
performed for the time horizons of 24 weeks, 48 weeks, respectively, which corre-
spond to the duration of therapy. Examined patients were adults who were either
treatment-experienced or treatment-naïve patients. RESULTS: The costs per re-
sponder in the group of previous relapser with the Telaprevir-combination-ther-
apy amount to €47,097.89. In the control-group, the standard-care of treatment
caused costs per responder of €80,563.05. For the combination-therapy with Tel-
aprevir this results in a cost-advantage of €33,465.16 (42%) per responder. Costs per
responder in the previous partial responders amount to €78,541.24 for the Telapre-
vir-containing regimen. In the control-group, the standard-therapy caused
€128,900.89 (cost advantage of €50,359.65 (39%) for the combination-therapy). The
costs-per-responder in the group of previous non-responders amount to
€159,790.80 for the triple-therapy, compared to the standard-therapy with
€386,702.66, resulting in a cost-advantage per responder of €226,911.86 (59%) for the
combination-therapy. Total costs of the Telaprevir-containing therapy with naïve-
patients amount to €54,410.53 per responder, compared to the control-group with
€43,943.48, causing a cost disadvantage of €10,467.05 per responders (24%) for the
combination-therapy with Telaprevir. Across all patient groups, a cost advantage
per responder of €50,298.68 (42%) incurred (standard therapy Peg-IFN2a and Riba-
virin: €118,559.52, combination-therapy with Telaprevir: €68,260.84).
CONCLUSIONS: The results of the analysis show that the combination-therapy
with Telaprevir is the dominant strategy in the treatment of chronic Hepatitis-C
Genotype-1 in Austria.
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